VIDEO: New data on allogeneic CAR T-cells
Click Here to Manage Email Alerts
In this video, Joshua Sasine, MD, PhD, assistant professor of medicine hematology and cellular therapy at Samuel Oschin Cancer Center Regenerative Medicine Institute, discusses new allogeneic chimeric antigen receptor T-cell therapy data.
The important data, which was presented at ASH, came in terms of the durability of the allogeneic CAR T cells, which Sasine said did not seem to be as durable as autologous CAR T cells.
"I think this might change the way we use these in the real-world setting, perhaps using them after auto CAR-T or in those patients who have auto CAR-T manufacturing failure or those who have aggressive disease," he said.
Collapse
Locke F, et al. Abstract 2. Presented at: ASH Annual Meeting and Exposition; Dec. 11-14, 2021; Atlanta.
Kamdar M, et al. Abstract 91. Presented at: ASH Annual Meeting and Exposition; Dec. 11-14, 2021; Atlanta.
Click Here to Manage Email Alerts